Pfizer Inc

In addition, the Governance & Sustainability Committee of the Board has oversight of the company's issues related to public policy, political spending policies and practices, and our lobbying activities. At least annually, the Committee receives a report from the company's U.S. Government Relations leaders regarding our work on legislative and regulatory policies, including an overview of the benefits derived from the company's association with certain trade and other organizations.

###### Governance — Continued ###### Political Contributions and Lobbying Activities We understand the impact public policy has on our ability to meet patient needs and provide value to our shareholders. As such, we actively participate in dialogue around public policy with lawmakers to advocate and educate, in addition to explaining our perspectives. We believe the business community has a responsibility to transparently engage in this space, given our extensive knowledge, research, and societal impact. Pfizer is a member of various industry and trade groups that represent both the pharmaceutical industry and the business community at large to bring about consensus on broad policy. In addition to trade group positions on healthcare policy issues, we realize these organizations may engage in a broad range of other issues that extend beyond the scope of what is of primary importance to Pfizer's business. If concerns arise about a particular issue, we convey our concerns, as appropriate. We believe there is value in making sure our positions on issues important to patients, Pfizer, and our industry are communicated and understood within those [organizations. In December 2021, Pfizer issued a report](https://cdn.pfizer.com/pfizercom/Gap_Analysis_Final_011023.docx) outlining the public policy positions of Pfizer and five trade associations across six areas of key public policy and ESG significance for Pfizer. The report also compares Pfizer and the trade associations' positions and describes the degree of alignment and areas of misalignment. Pfizer will update this report periodically, as needed. [Pfizer's corporate political contributions and lobbying](https://www.pfizer.com/about/programs-policies/political-partnerships) [activities are focused on promoting the interests of the](https://www.pfizer.com/about/programs-policies/political-partnerships) patients we serve and our company, without regard to the personal political preferences or affiliations of any of our employees, officers, or board members. The company's corporate political contributions and lobbying activities are subject to robust internal procedures designed to align these efforts with our public policy priorities, applicable law, and patient-centric agenda. The company has an extensive training and reporting program in place designed to ensure compliance with applicable laws and regulations as well as Pfizer's internal standards.

The Governance & Sustainability Committee (G&S Committee) of the Board is responsible for overseeing Pfizer's ESG strategy, risk management, reporting, and practices. Additionally, and as detailed in this Impact Report, our other Board Committees oversee specific elements of ESG associated with their respective areas of responsibility and risk oversight. [...] Throughout 2023, the G&S Committee received regular updates from the Chief Sustainability Officer and other leaders about Pfizer's progress towards advancing its ESG priorities and public commitments to climate sustainability and colleague diversity, equity, and inclusion. The Committee then shared this information with the Board. The Committee was also kept informed about potential changes within the dynamic external ESG landscape, stakeholder expectations, and new ESG reporting requirements. [...] The Board of Directors is engaged in and supports ESG at Pfizer. The G&SC is primarily responsible for oversight of our ESG strategy, reporting, policies, and practices. The G&SC regularly receives updates from management on Pfizer's progress as measured against the company's ESG strategy, metrics, and goals. The G&SC also receives updates on the regulatory environment that may impact our ESG strategy and reporting requirements. The G&SC has oversight of human capital management, including succession planning; culture; diversity, equity and inclusion; pay equity; talent management; political and lobbying activities; climate change program; reputational risk factors; and Board diversity. [...] Pfizer's corporate political contributions and lobbying activities are subject to robust internal procedures designed to align these efforts with our public policy priorities, applicable law, and patient-centric agenda. The company has an extensive training and reporting program in place designed to ensure compliance with applicable laws and regulations as well as Pfizer's internal standards.

Describe the process(es) your organization has in place to ensure that your engagement activities are consistent with your overall climate change strategy[…]Our engagement activities with policy makers, trade associations, and other organizations are guided by our Climate Change Position Statement, which outlines Pfizer's approach to climate change and the policies that will help support Pfizer's climate change strategy. Our support of trade associations is evaluated annually by the company's U.S. Government Relations leaders based on these organizations' expertise in healthcare policy and advocacy and support of key issues of importance to Pfizer. In addition to their positions on healthcare policy issues, we realize these organizations may engage in a broad range of other issues that extend beyond the scope of what is of primary importance to Pfizer. If concerns arise about a particular issue, we convey our concerns, as appropriate, through our colleagues who serve on the boards and committees of these groups. We believe there is value in making sure our positions on issues important to Pfizer and our industry are communicated and understood within those organizations. Pfizer's participation as a member of these various industry and trade groups comes with the understanding that we may not always agree with the positions of the larger organization and/or other members.

Does your organization have a public commitment or position statement to conduct your engagement activities in line with the goals of the Paris Agreement?[…]Yes

Describe the process(es) your organization has in place to ensure that your external engagement activities are consistent with your climate commitments and/or climate transition plan?[…]Our climate-related engagement activities with policy makers, trade associations, and other organizations are guided by our Climate Change Position Statement, which outlines Pfizer's approach to climate change and the policies that will help support Pfizer's climate change strategy. Our support of trade associations is evaluated annually by the company's U.S. Government Relations leaders based on these organizations' expertise in healthcare policy and advocacy and support of key issues of importance to Pfizer. In addition to their positions on healthcare policy issues, we realize these organizations may engage in a broad range of other issues that extend beyond the scope of what is of primary importance to Pfizer. If concerns arise about a particular issue, we convey our concerns, as appropriate, through our colleagues who serve on the boards and committees of these groups. We believe there is value in making sure our positions on issues important to Pfizer and our industry are communicated and understood within those organizations. Pfizer's participation as a member of these various industry and trade groups comes with the understanding that we may not always agree with the positions of the larger organization and/or other members.